ArticleEuropean journal of medical research2025
Tumor markers level profile in dermatomyositis, systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and ovarian cancer.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune diseases (AID) have been showed to be susceptibility to malignancy. This study aimed to analyzed the profile of serum tumor markers in four common autoimmune disease.
methodsPatients with dermatomyositis (DM, n = 132), Systemic sclerosis (SSc, n = 77), Systemic lupus erythematosus (SLE, n = 191), Rheumatoid arthritis (RA, n = 160) and ovarian cancer (n = 250) were included in this study. Twelve tumor markers (CA724, AFP, FRT, NSE, CA19-9, CA125, CYFRA21-1, CA153, β-HCG and HE4) levels and abnormal rate in these patients were retrospective statistics. The tumor markers profiles were compared among the different AID.
resultsCompared with ovarian cancer (OV) patients, there were no significant differences for the levels and abnormal rates of CYFRA21-1/HE4/CA50/FRT in AID patients. The levels and abnormal rates of CA724/FRT/CA125/NSE were higher in OV patients than that in AID patients. 75% AID patients have at least one elevated tumor marker. 69.46% AID patients have 2-5 elevated tumor markers. All the 12 tumor markers were negative in 16.67, 19.74, 27.23 and 32.70% of DM, SSc, SLE and RA patients. Except CA50, the levels of the other eleven tumor markers were significantly different between DM/SSc/SLE/RA. Except AFP/β-HCG/SCC, the abnormal rate of the other tumor markers were significantly different between these AID.
conclusionsThe increased levels of tumor makers were common in four major AID, and the profile of tumor makers were significantly different among these AID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.